News

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...
Both time-limited therapy and continuous therapy for chronic lymphocytic leukemia (CLL) have potential benefits and drawbacks. The best choice, a joint decision between clinician and patient, should ...
AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non-small cell lung cancer, adding to its robust oncology portfolio. Despite ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...
MedPage Today on MSN25d
Monotherapy for CLL
Particularly for older patients or those who are less able to travel to a clinician's office, monotherapy may better suit their therapeutic needs and lifestyles.Monotherapy is a common approach in CLL ...
A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the treatment of ...
AstraZeneca PLC (LSE/STO/Nasdaq:LON: AZN) announced the European Union’s approval of its fixed-duration Calquence (acalabrutinib) regimens for the treatment of adult patients with previously untreated ...
AstraZeneca PLC (LSE/STO/Nasdaq:LON: AZN) announced the European Union’s approval of its fixed-duration Calquence (acalabrutinib) regimens for the treatment of adult patients with previously ...
A fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the treatment of ...